Multiple Myeloma EHA 2017. LB2236. Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd)…
jwood@krftwrk.caAugust 1, 2017
Chronic Lymphocytic Leukemia: Ibrutinib Monotherapy EHA 2017. S769. Long-term Efficacy and Safety with Ibrutinib in…
jwood@krftwrk.caAugust 1, 2017
On January 13th, 2017 CARE™ faculty specialists representing the fields of gastroenterology, hematology, oncology, respirology…
jwood@krftwrk.caJanuary 23, 2017
ASH 2016 Abstract 234. Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As…
jwood@krftwrk.caJanuary 10, 2017
ASH 2016 Abstract 637. Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who…
jwood@krftwrk.caJanuary 10, 2017
ASH 2016 Abstract 6. Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated…
jwood@krftwrk.caJanuary 10, 2017
ASH 2016 Abstract 1151. Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed…
jwood@krftwrk.caJanuary 10, 2017
ASH 2016 Abstract 1105. Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination…
jwood@krftwrk.caJanuary 10, 2017
Biologic therapy has revolutionized the treatment of IBD and improved patient outcomes drastically. Many of…
jwood@krftwrk.caDecember 13, 2016
